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Human thyroid cancer cell lines are the most used models for thyroid cancer studies.
They must be used with detailed knowledge of their characteristics. These in vitro cell
lines originate from differentiated and dedifferentiated in vivo human thyroid tumors.
However, it has been shown that mRNA expression profiles of these cell lines were
closer to dedifferentiated in vivo thyroid tumors (anaplastic thyroid carcinoma, ATC) than to
differentiated ones. Here an overview of the knowledge of these models was made. The
mutational status of six human thyroid cancer cell lines (WRO, FTC133, BCPAP, TPC1,
K1, and 8505C) was in line with previously reported findings for 10 genes frequently
mutated in thyroid cancer. However, the presence of a BRAF mutation (T1799A: V600E) in
WRO questions the use of this cell line as a model for follicular thyroid carcinoma (FTC).
Next, to investigate the biological meaning of the modulated mRNAs in these cells, a
pathway analysis on previously obtained mRNA profiles was performed on five cell lines.
In five cell lines, the MHC class II pathway was down-regulated and in four of them,
ribosome biosynthesis and translation pathways were up-regulated. mRNA expression
profiles of the cell lines were also compared to those of the different types of thyroid
cancers. Three datasets originating from different microarray platforms and derived from
distinct laboratories were used. This meta-analysis showed a significant higher correlation
between the profiles of the thyroid cancer cell lines and ATC, than to differentiated thyroid
tumors (i.e., PTC or FTC) specifically for DNA replication. This already observed higher
correlation was obtained here with an increased number of in vivo tumors and using
different platforms. In summary, this would suggest that some papillary thyroid carcinoma
or follicular thyroid carcinoma (PTC or FTC) cell lines (i.e., TPC-1) might have partially lost
their original DNA synthesis/replication regulation mechanisms during their in vitro cell
adaptation/evolution.
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INTRODUCTION
The experimental study of human cancers uses in vitro and
in vivomodels. Among the various possible experimental models,
human cancer cell lines are frequently used (van Staveren et al.,
2009). They have retained hallmarks of cancer cells; they are pure,
genetically identical, easily propagated and can be genetically
manipulated. A cell line originates from a tissue and is obtained
by selection of the most rapidly proliferating and resistant cells in
monolayer during passages.
Results obtained on a cell line are sometimes directly extrapo-
lated for in vivo cancers which produced this cell line (Yeung et al.,
2007; Wang et al., 2008). However, the representativity of the can-
cer cell line may be distorted by a cross contamination of one cell
line by another (Ribeiro et al., 2008; Schweppe et al., 2008), an
in vitro evolution of the cell line (van Staveren et al., 2009), a
strong genomic instability due to the number of passages or a risk
of infection (Harlin and Gajewski, 2008). Thus, a systematic veri-
fication of the status of these cell lines is important (van Staveren
et al., 2007; Ribeiro et al., 2008; Schweppe et al., 2008).
Thyroid cancer is the most frequent endocrine cancer (Kondo
et al., 2006; Sipos and Mazzaferri, 2010). There are various types
of thyroid carcinomas, the carcinomas from thyrocyte are largely
the most frequent: papillary thyroid carcinoma (PTC), follicu-
lar thyroid carcinoma (FTC) anaplastic thyroid carcinoma (ATC)
and an intermediate form between PTC/FTC and ATC, the poorly
differentiated thyroid cancer. Each type is characterized by a
set of mutations leading to increased cellular proliferation and
dedifferentiation (Catalano et al., 2010).
PTC is the most frequent type of human thyroid carcinoma
(Kondo et al., 2006). The genetic alterations most often found in
PTC are BRAF point mutations, accounting for 40–60% of the
cases, and RET/PTC rearrangements which are present in about
20% of the cases. Themost frequent BRAFmutation occurs in the
serine/threonine kinase domain (V600E) and leads to the consti-
tutive kinase activity of the protein (Xing, 2010). This mutation
could be a keymutation for the treatment and the diagnosis of the
most aggressive PTC (Nucera et al., 2010; Xing, 2010). RET/PTC
rearrangements are the result of a fusion between the 3′ end of
a receptor of the tyrosine kinase family (RET) and the 5′ end
of a gene constitutively expressed in thyrocytes. The most fre-
quent rearrangements of this type are RET/PTC1 and RET/PTC3.
The fusion results in the constitutive activation of the truncated
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tyrosine kinase portion of RET by autophosphorylation due to the
dimerization domain of the heterologous gene (Catalano et al.,
2010).
The genetic changes most often found in FTC are RAS point
mutations (approximately 45% of the cases) and PAX8/PPARγ
rearrangements (approximately 35% of the cases). Mutations of
the RAS gene activate the mitogenic MAPK and the PI3K path-
ways. PAX8/PPARγ rearrangements are the result of a fusion
between the 5′ end of the PAX8 transcription factor and the
3′ end of PPARγ, a member of the nuclear hormone recep-
tor superfamily, constitutively expressed in thyrocytes. Different
rearrangements between the 2 genes have been described, and
sometimes reported within a single tumor (Lacroix et al., 2004).
PAX8/PPARγ chimeric proteins have a dominant negative effect
on the wild-type PPARγ. In addition to these, alterations in the
tumor suppressor gene PTEN (10% of the cases) and the PI3KCA
oncogenes (10% of the cases) have been described in this tumor
type.
ATC is the most dedifferentiated, aggressive thyroid cancer
(Kondo et al., 2006). The genetic alterations most often observed
are the ones already described in PTC and FTCwith the exception
of RET/PTC and PAX8/PPARγ rearrangements, but in addition
also include mutations in TP53 and β-catenin genes.
For each type of human thyroid carcinoma, derived cell lines
have been generated. In this study, we used six different human
cancer cell lines derived from different types of thyroid can-
cers. The WRO (Estour et al., 1989) and FTC133 (Goretzki
et al., 1990) cell lines are derived from FTC; the BCPAP (Fabien
et al., 1994) commonly known as a PTC cell line is derived
from a poorly differentiated PTC; TPC1 (Tanaka et al., 1987)
and K1 (Challeton et al., 1997) cell lines are derived, respec-
tively, from PTC and from a metastasis of a well-differentiated
PTC (Ribeiro et al., 2008); the 8505C (Ito et al., 1993) cell
line from ATC. These six cell lines are among those mostly
used for thyroid cancer research. The mutational status of each
of these cell lines was investigated and compared to the liter-
ature. Next, pathways were further investigated by using our
previously obtained data on mRNA expression patterns of these
cell lines that had been compared to primary cultured nor-
mal human thyrocytes (van Staveren et al., 2007). Previously we
showed thatmRNA expression profiles from different human thy-
roid tumor cell lines, including cell lines of the present study,
evolved in vitro into similar phenotypes with mRNA expres-
sion profiles closer to undifferentiated in vivo thyroid tumors
(ATC) than to differentiated thyroid cancers (PTC and FTC)
(van Staveren et al., 2007). To investigate this further, a correla-
tion analysis between mRNA expression profiles from cell lines
and mRNA expression profiles from each in vivo thyroid tumor
type was performed by using three datasets generated in two dif-
ferent laboratories that were derived from different microarray
platforms.
MATERIALS AND METHODS
CELL CULTURE
Cell lines were obtained from various laboratories. The WRO,
FTC133, BCPAP, and 8505C cell lines were received from Prof.
G. Brabant (Medizinische Hochschule, Hannover, Germany);
the TPC1 cell line from Prof. M. Mareel (University of Ghent,
Belgium); the K1 cell line from Dr. Zaruhi Poghosyan (Cardiff
University, Scholl of Medecine, Cardiff, UK). The BCPAP, TPC1
and 8505C cell lines were cultured in RPMI 1640 (w L-glutamate)
completed by foetal bovine serum (10%), penicillin/streptomycin
(2%) and amphotericine B (1%); the FTC133, WRO and K1
cell lines were cultured in Dulbecco’s Modified Eagle Medium,
Nutrient mixture F-12 (1:1, by volume) completed by foetal
bovine serum (10%), penicillin/streptomycin (2%), ampho-
tericine B (1%). All culture reagents were purchased from Gibco
(Paisely, UK).
RNA EXTRACTION
After removal of the culture medium, 2ml of TRIzol Reagent
(Ambion, Austin, USA) was added to the cells grown in 10 cm
dishes. Total RNA was extracted according to the manufacturer’s
instructions, followed by purification on miRNeasy columns
(QIAGEN, Hilden, Germany). RNA was spectrophotometrically
quantified, and its integrity was verified by automated gel elec-
trophoresis (Experion, Bio-Rad, Hercules, USA).
RT-PCR
After a DNase treatment with DNase I Amplification Grade kit
(Invitrogen, Carlsbad, USA), 1μg of total RNA was used for
reverse transcription using hexamers [(3.6μg/μl) (Roche, Basel,
Switzerland)] and reverse transcriptase (Superscript II RNase
H Reverse Transcriptase kit, Invitrogen). The PCR reactions
were performed with the recombining Taq DNA polymerase kit
(Invitrogen). Each PCR reaction was performed in the presence
of 5μl 10X PCR buffer, 1.5μl MgCl2 (50mM), 1μl dNTP mix
(10mM, Invitrogen), 1μl of the forward and the reverse primer
(10μM each), 0.4μl Taq DNA polymerase (5U/μl), 2μl DNA
from the RT reaction and 38.1μl of water. Primers and PCR
conditions are detailed in Table 1.
SEQUENCING
PCR products were purified with the QIAquick PCR purifica-
tion kit (QIAGEN) according to the manufacturer’s instructions.
Sequencing was performed with the BigDye Terminator V3.1
Cycle Sequencing Kit (Applied Biosystems, Foster City, USA) with
the sequencer ABI PRISM 3130 (Applied Biosystems) and the
genetic analysis program 3130-XI. Sequences were analyzed with
BLAST (Basic Local Alignment Search Tool program) fromNCBI
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
PRE-PROCESSING OF THE DIFFERENT DATASETS
A merged file was created which contained three differ-
ent datasets derived from three different microarray plat-
forms. The first dataset consisted of five cell lines hybridized
on IRIBHM custom slides, using primary cultured normal
thyrocytes as a reference (www.ulb.ac.be//medecine/iribhm/
microarray/data/) (van Staveren et al., 2007). The second dataset
was composed of 11 ATC, 49 PTC, and 45 normal thyroid
tissues hybridized on the Affymetrix HG U133 Plus 2.0 plat-
form (GSE33630). The third dataset contained 4 ATC, 51
PTC, 13 FTC, and 4 normal thyroid tissues hybridized on
the Affymetrix HG U133A platform (Giordano et al., 2005)
(GSE27155). Each platform has been validated in previous
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Table 1 | Targeted exons, sequences of the primers used for PCR amplification, amplicon length and PCR conditions for each investigated gene.
Gene Targeted
exons(s)
Forward primer (5′–>3′) Reverse primer (5′–>3′) Size (bp) PCR conditions
BRAF 14 and 15 GCACAGGGCATGGATTACTT GATGACTTCTGGTGCCATCC 194 Std but Tm at 55◦C
NRAS 3 CGCACTGACAATCCAGCTAA TCGCTTAATCTGCTCCCTGT 255 Std
HRAS 3 GGAAGCAGGTGGTCATTGAT ACGTCATCCGAGTCCTTCAC 204 Std
KRAS 3 AGAGAGGCCTGCTGAAAATG TTGACCTGCTGTGTCGAGAA 200 Std
TP53-1 2, 3, 4, 5 GTGACACGCTTCCCTGGAT ACACGCAAATTTCCTTCCAC 658 Std
TP53-2 5, 6, 7 CCCTTCCCAGAAAACCTACC AGCTGTTCCGTCCCAGTAGA 518 Std
TP53-3 6, 7, 8, 9, 10, 11 GCTGCTCAGATAGCGATGGT GTGGGAGGCTGTCAGTGG 660 Std
PI3KCA-1 9, 10, 11 TGACTGGTTCAGCAGTGTGG GGCCAATCTTTTACCAAGCA 341 Std
PI3KCA-2 20, 21 TTTTGACACAGGATTTCTTAATAGTGA GGTCTTTGCCTGCTGAGAGT 418 Std but Tm at 55◦C
PAX8/PPARγ Pax8: 8, 9, 10
PPARγ: 3
8, 9
8, 10
8, 9
GCAACCTCTCGACTCACCAG (PAX8) CATTACGGAGAGATCCACGG (PPARγ) 407
305
217
108
Std
RET/PTC1 RET:12, 13
H4: 1
GGCACTGCAGGAGGAGAAC (H4) GATGACATGTGGGTGGTTGA (RET) 277 Std
RET/PTC3 RET:12, 13
ELE1: 7
AAGCAAACCTGCCAGTGG (ELE1) TGCTTCAGGACGTTGAAC (RET) 240 Std but with 30 cycles
PTEN-1 4, 5, 6 GACATTATGACACCGCCAAA CGCCACTGAACATTGGAATA 405 Std
PTEN-2 6, 7, 8, 9 GCTACCTGTTAAAGAATCATCTGGA TGACGGCTCCTCTACTGTTTT 530 Std but Tm at 48◦C
PBGD 11, 12, and 13 AAGGACCAGGACATCTTGGA AACTGTGGGTCATCCTCAGG 266 Std but Tm at 55◦C
Std: Standard conditions: 94◦C for 5 min followed by 35 cycles consisting of incubations at 94◦C for 30 s, 60◦C (Tm) for 1 min and 72◦C for 1 min. At the end of
cycles the PCR mixtures were incubated at 72◦C for 10 min. PBGD gene was used as a positive control for amplification. For each PCR, a negative control (the
amplification mix without DNA) was used to detect possible contamination.
studies [Giordano et al., 2005; van Staveren et al., 2006;
Hébrant et al., 2012; Dom et al. (submitted)]. For both inde-
pendent Affymetrix platforms, mRNA expression profiles of
normal tissues were pooled as a reference and an mRNA
expression ratio between each tumor and the normal refer-
ence was calculated for each gene. For the comparison of cell
lines with in vivo thyroid tumors, only genes were included
that was expressed in both cell lines and primary thyrocytes.
Finally, the merged file contained the mRNA expressions of
2392 genes, expressed in log2, present on the three different
microarray platforms.
DAVID PATHWAY ANALYSIS
In order to investigate the biological meaning of the modulated
mRNAs, Database for Annotation, Visualization and Integrated
Discovery (DAVID pathway analysis) (Huang da et al., 2009) was
used. For the cell line analyses, only genes showing a regulation
of at least |0.58| in log2, i.e., 1.5-fold or more were included. To
calculate the background, all the genes present on the IRIBHM
custom slides were used. For the comparison between ATC and
cell lines, only significant commonly regulated genes were consid-
ered. The background was calculated using all the genes present
in the merged file. For both analyses, a pathway was selected
when its False Discovery Rate (FDR) was <5%. The analysis
was performed separately for up-regulated and down-regulated
genes.
CORRELATION OF mRNA EXPRESSION BETWEEN in vitro HUMAN
THYROID CANCER CELL LINES AND in vivo HUMAN THYROID TUMORS
Spearman’s correlation coefficients were computed using R (ver-
sion 2.14.1). Based on the merged file, correlation coefficients
between gene expression profiles of ATC and thyroid cancer cell
lines were compared to correlation coefficients between gene
expression profiles of PTC or FTC and thyroid cancer cell lines,
using a Mann–Whitney U-test. This assessed whether ATC and
cell lines had more similar mRNA expression profiles than FTC
or PTC and cell lines. Comparisons of those coefficients were
made between samples hybridized on the same microarray plat-
form. 2D-multidimensional scaling was plotted based on those
Spearman correlation coefficients using the R function isoMDS
from the package MASS v.7.3–18.
ANALYSIS OF THE GENES COMMONLY AND OPPOSITELYMODULATED
IN ATC in vivo AND CANCER CELL LINES
Scores and q-values were computed based on a slightly mod-
ified version of Rank Products (Breitling et al., 2004) to find
genes regulated in ATC compared to normal tissues and in cell
lines compared to primary cultured normal thyrocytes. Rank
Products is a non-parametric method allowing to study differ-
ential expression and to integrate the information of different
datasets regardless of the potential technical differences, e.g.,
from different laboratories or different microarray platforms. It
has been shown to outperform SAM (Zang et al., 2007) and is
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more powerful with fewer samples than t-test based statistics.
The genes with a q-value ≤ 0.05 were selected from ATC and cell
lines. Genes that were regulated in the same direction in ATC
and cell lines were kept and are shown in a heatmap using R
library: gplots v.2.10.1 (http://cran.r-project.org/web/packages/
gplots/index.html). Similarly, genes that had significant regula-
tions in opposite directions between ATC and cell lines were
further analyzed.
RESULTS
MUTATIONAL STATUS
The mutational status was investigated for known thyroid onco-
genes and tumor suppressor genes in six human thyroid cancer
cell lines. For each cell line, the presence of point mutations
in BRAF, NRAS, HRAS, KRAS, TP53, PI3KCA, PTEN genes
was explored as well as the presence of RET/PTC1, RET/PTC3,
and PAX8/PPARγ rearrangements. Therefore, primers were
designed to target the point mutations and the rearrange-
ments most frequently found in thyroid carcinomas (Kondo
et al., 2006) and each mutation was verified by sequencing
both DNA strands. The results are summarized in Table 2.
Neither NRAS, HRAS, KRAS point mutations nor RET/PTC3 or
PAX8/PPARγ gene rearrangements were detected in any of the
six cell lines. As reported earlier, FTC133 cells showed PTEN
and TP53 mutations, BCPAP and 8505C cells showed BRAF
and TP53 mutations, and TPC1 cells harbored the RET/PTC1
gene rearrangement.WRO cells presented the heterozygousBRAF
T1799A (V600E) mutation and K1 the heterozygous PIK3CA
G1624A (E542K) mutation, in addition to the BRAF mutation
(Figure 1).
PATHWAY ANALYSIS OF THE CELL LINES
To define the modulated pathways in thyroid cancer cell lines,
the genes from previously published mRNA expression profiles
from five thyroid cancer cell lines (FTC133, BCPAP, 8505C, TPC1,
WRO) were further analysed (van Staveren et al., 2007). These
data reported the differential mRNA expression between each cell
line and a pool of human primary cultured normal thyrocytes.
DAVID pathway analyses were performed on each individual cell
line (Supplementary information A). Four of the five cell lines,
i.e., WRO, BCPAP, TPC1, and 8505C, showed commonly regu-
lated pathways. An upregulation of ribosome biosynthesis and
translation was detected in these four cell lines, and in addition,
expression of genes involved in the cell cycle was increased in
WRO and BCPAP cells. Expression of genes involved in DNA
replication was up-regulated in both BCPAP and 8505C cells.
FIGURE 1 | (A) Sequence of BRAF in WRO cells. The arrow shows the
T1799A mutation. (B) Sequence of PI3KCA in K1 cells. The arrow indicates
the G1624A mutation.
Table 2 | Mutational status of six human thyroid cancer cell lines derived from three types of thyroid carcinomas.
Cell lines BRAF NRAS HRAS KRAS PI3KCA PTEN TP53 RET/PTC1 RET/PTC3 PAX8/PPARγ
WRO
(FTC)
GTG->
GAG
V600E*
wt wt wt wt wt wt − − −
FTC133
(FTC)
wt wt wt wt wt CGA->TGA
R130STOP
CGT->CAT
R273H
− − −
B-CPAP
(PTC)
GTG->
GAG
V600E
wt wt wt wt wt GAC->TAC
D259Y
− − −
TPC1
(PTC)
wt wt wt wt wt wt wt + − −
K1
(PTC)
GTG->
GAG
V600E*
wt wt wt GAA->AAA
E542K*
wt CGA->CGC
R213R
− − −
8505c
(ATC)
GTG->
GAG
V600E
wt wt wt wt wt CGG->GGG
R248G
− − −
Differences between these results and the published data are indicated in bold. These results were compared to previously published data for WRO (Namba et al.,
2003; Xu et al., 2003; Garcia-Rostan et al., 2005; Palona et al., 2006; Schweppe et al., 2008), FTC133 (Ricarte-Filho et al., 2009), B-CPAP (Garcia-Rostan et al.,
2005; Meireles et al., 2007; Ricarte-Filho et al., 2009), TPC1 (Meireles et al., 2007; Ricarte-Filho et al., 2009), K1 (Garcia-Rostan et al., 2005; Meireles et al., 2007;
Ricarte-Filho et al., 2009) and 8505c (Garcia-Rostan et al., 2005; Meireles et al., 2007; Ricarte-Filho et al., 2009; Nucera et al., 2010) cell lines. *, heterozygous
mutation; wt, wild-type genotype (no mutation); +, presence of the gene rearrangement; −, absence of the gene rearrangement.
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Furthermore, in all cell lines, expression of genes involved in
MHC class II biosynthesis was down-regulated and in four cell
lines (not in 8505C) the expression of genes involved in nega-
tive regulation of cell death/apoptosis was also down-regulated.
In both 8505C and TPC1 cells, expression of genes involved in
the immune response was decreased and for the latter, a decrease
in the protease inhibitor pathway was also observed. In contrast,
the FTC133 cell line showed some differences in the regulated
pathways. Although the downregulation of the MHC class II and
the negative regulation of cell death/apoptosis were present, no
increase of expression of genes involved in ribosome biosynthe-
sis and translation were observed. Instead, FTC133 cells showed a
strong upregulation of global RNA processing.
CORRELATIONS BETWEENmRNA EXPRESSION PROFILES OF in vitro
THYROID CANCER CELL LINES AND mRNA EXPRESSION PROFILES OF
in vivo THYROID TUMORS
Two different datasets of mRNA expression profiles from in vivo
human thyroid tumors were correlated to the mRNA profiles
of the WRO, FTC133, BCPAP, TPC1, and 8505C cell lines. One
dataset was composed of 11 ATC and 49 PTC hybridized on
Affymetrix HG U133 Plus 2.0 arrays. The other dataset con-
sisted of 4 ATC, 13 FTC, and 51 PTC hybridized on Affymetrix
HG U133A arrays. For both independent datasets, the Spearman
correlation coefficient was the highest between cell lines and
ATC compared to the cell lines and PTC or FTC (Figures 2A,B).
Furthermore, there was a significant difference between the corre-
lations of ATC versus cell lines compared to those calculated with
the PTC or FTC profiles (Figures 2A,B).
These results are in line with previous results which showed
by 2D-multidimensional scaling analysis the highest similarity
between cell lines and ATC, compared to cell lines with PTC or
FTC (van Staveren et al., 2007). Thus, this already observed rela-
tion could be confirmed in the present study using more tumor
samples that had been hybridized on different microarray plat-
forms. As shown in Figure 2C, although a platform effect was
visible, in both independent datasets ATC were closer to cell lines.
ANALYSIS OF THE GENES COMMONLY AND OPPOSITELYMODULATED
IN ATC in vivo AND CANCER CELL LINES
To further investigate the similarity between ATC and cell lines,
their mRNA expression profiles, obtained on different microarray
platforms, were compared. Rank Products and SAM were used to
find genes significantly regulated in the same direction or in the
opposite direction comparing ATCwith cell lines. Sixty-one genes
were found to be up-regulated in both ATC and cell lines and
eighty-four genes were found to be commonly down-regulated
(Figure 3). Eighteen genes were regulated in an opposite direction
between ATC and cell lines.
To gain more insight into those regulations, a DAVID pathway
analysis was performed (Supplementary information B). Some
common up-regulated genes in ATC and cell lines are involved
in DNA replication and DNA metabolic processes, e.g., TOP2A,
MCM7, CHAF1A, or HMGB2. Most of the 18 genes that were
regulated in an opposite direction were down-regulated in cell
lines but up-regulated in ATC. They are involved in MHC class
II pathway or in cell adhesion, e.g., HLA-DPB1, HLA-DQB1,
HLA-DRA, ICAM1, CCL2, or COL6A3.
DISCUSSION
In this work, the aim was to further investigate the characteris-
tics for different human thyroid cancer cell lines. First, genetic
alterations in these cell lines were confirmed. Second, regulated
pathways in these cell lines were further explored. Third, cor-
relations, based on gene expressions, between in vitro human
thyroid cell lines and in vivo human thyroid tumors were anal-
ysed. Finally, the similarity between cell lines and ATCwas further
explored on the gene level.
MUTATIONAL STATUS
We have investigated the mutational status of 10 commonly
mutated genes in thyroid cancer by using six different cell lines.
STR analyses on these cell lines (van Staveren et al., 2007 and
Supplementary information C) showed that they were identical
to those published by Schweppe and coauthors (Schweppe et al.,
2008). No differences with reported literature data were observed
for the mutational status of these genes in BCPAP, FTC133, TPC1,
and 8505C cell lines. However, a difference could be observed for
the status of BRAF in WRO and PI3KCA in K1 cells.
For WRO cells described as a FTC cell line, the BRAF T1799A
(V600E) mutation was detected although these cells were origi-
nally described as BRAF wild-type (Namba et al., 2003; Xu et al.,
2003) and are still frequently used as such today (Palona et al.,
2006; Liu et al., 2007; Burrows et al., 2010; Hou et al., 2010).
The presence of a BRAF mutation in these cells was neverthe-
less reported by Schweppe and coworkers (Schweppe et al., 2008)
and they demonstrated that the cell line was not contaminated
by another cell line harboring this mutation. It has been sug-
gested that two different WRO cell lines were distributed. The
WRO cells from Schweppe’s laboratory has the same DNA pro-
file (STR analysis) than ours (van Staveren et al., 2007; Schweppe
et al., 2008), but is different from that of the European Collection
for Cell Culture. The presence of this mutation in WRO cells was
unexpected because this cell line has been derived from a FTC,
and the V600E BRAF mutation is described as a specific char-
acteristic for PTC. This might suggest that, in spite of its initial
diagnosis of follicular cancer, the tumor at the origin of the cre-
ation of the WRO cell line would have rather been a papillary
type. The presence of a mixture of BRAF mutated and non-
mutated cells in the original tumor sample cannot be excluded.
However, it may also be proposed that this cell line acquired
this mutation in vitro, during its successive divisions in an arti-
ficial environment of selection (van Staveren et al., 2007, 2009).
These observations question the representativity and the utility of
this cell line as a model for human FTC and show the necessity
of a systematic check of the cell lines. Furthermore, the V600E
BRAF mutation is not specific of thyroid cancer. The origin of
the WRO cell line as a thyroid cancer cell line is not completely
certified.
For the K1 cell line, a mutation in the PI3KCA gene has been
reported previously. By sequencing, the presence of a G1624A
substitution in codon 542 (E542K) was confirmed in accor-
dance with previously published data (Garcia-Rostan et al., 2005;
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FIGURE 2 | Boxplots of correlations between cell lines and in vivo
thyroid tumors. (A and B) Correlations were calculated based on 2,392
mRNA expressions comparing human thyroid cancer cell lines (CL) with
different types of in vivo human thyroid tumors by using three datasets.
The first was composed of five thyroid cancer cell lines (WRO, FTC133,
BCPAP, TPC1, 8505C) hybridized on IRIBHM custom slides. The second
was composed of 11 ATC and 49 PTC hybridized on Affymetrix HG U133
Plus 2.0 (A). The third was composed of 4 ATC, 13 FTC, and 51 PTC
hybridized on Affymetrix HG U133A (B). P -values indicate whether ATC
and cell lines had more similar profiles than FTC or PTC and cell lines.
P -values were significant for both independent datasets.
(C) 2D-multidimensional scaling representation of the mRNA expression
profiles of cell lines, ATC, PTC, and FTC based on 2392 mRNA
expressions.
Meireles et al., 2007). In another publication, Ricarte-Filho et al.
(Ricarte-Filho et al., 2009) reported the presence of a E545K
(G1633A) mutation in these cells. We could observe a glu-
tamic acid at position 545. Thus, the G1633A mutation might
potentially exist but was never described as a new mutation by
Ricarte–Filho et al.
PATHWAY ANALYSIS OF THE CELL LINES
Pathway analysis of mRNA expression profiles in WRO, FTC133,
BCPAP, TPC1, and 8505C cell lines was performed. In general,
the cell lines abrogate gene expressions which are not necessary
for their propagation in in vitro cultures and express genes that
promote in growth and survival. The common loss of MHC2
biosynthesis and, in some cell lines, of the immune response,
can be explained because they would be not necessary for a cell
in culture. The common downregulation of the negative regula-
tion of the cell death/apoptosis pathway might be explained by an
ineffective feedback resulting from an excess of proliferation.
Except for FTC133 cells, a common overexpression of ribo-
somal biosynthesis and translation pathways were observed. This
may reflect the increase in proliferation of the cancer cells induced
by gene mutations. However, some recent studies suggest that
the up-regulation of the ribosomal biosynthesis may induce can-
cer by a downregulation of the cell tumor suppressor potential
(Montanaro et al., 2012). For our data, the two explanations
are possible. However, the growth rate of the FTC133 cell line
is higher than for the other cell lines [Dom et al. (submitted)].
For this cell line, an overexpression of the global RNA processing
including alternative splicing was observed. This might allow the
strong increase in proliferation of this cell line.
CORRELATIONS BETWEEN mRNA EXPRESSION PROFILES OF in vitro
THYROID CANCER CELL LINES AND mRNA EXPRESSION PROFILES OF
in vivo THYROID TUMORS
The correlations of the mRNA expression profiles between cell
lines and ATC were significantly higher than those compared
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FIGURE 3 | Heatmap of 145 mRNA expressions in thyroid cancer cell
lines (CL) and in human thyroid tumors. These genes were the most
commonly up and down-regulated genes in ATC and in the cell lines. The
level of modulation of these genes in PTC and FTC are also shown. Profiles
of the five cell lines are underlined in black. Profiles of the samples hybridized
on Affymetrix HG U133 Plus 2.0 platform and on Affymetrix HG U133A
platform are underlined in blue and violet respectively. Genes are indicated by
their official gene symbols.
to other in vivo differentiated thyroid tumors (PTC, FTC). By
using data derived from different microarray platforms and from
two different laboratories, thereby including a larger number
of in vivo tumors, the current data confirm our previous find-
ing that mRNA expression profiles from human thyroid tumor
cell lines with different origins are the closest to undifferenti-
ated in vivo tumors (van Staveren et al., 2007). This is explained
by an in vitro evolution of the cell lines that should be taken
into account when extrapolating results obtained from these cells.
An in vitro cell line is the result of the selection of the most
rapidly proliferating and resistant cells during numerous pas-
sages. Cell lines contain one cell type, whereas in vivo tumors
are complex mixtures of various cell types. Therefore, it might
be argued that the comparisons between thyroid cancer cell lines
and in vivo thyroid tumors could be affected by the presence of
different cell types such as for instance lymphocytes, endothe-
lial cells. However, in this study only genes were compared that
were expressed in thyrocytes, i.e., were expressed in both thyroid
cancer cell lines and in primary thyrocytes. This should reduce
the impact of the potential presence of different cell types but,
unfortunately, it cannot assure the complete elimination of a
background due to commonly expressed genes in the different cell
types.
ANALYSIS OF THE GENES COMMONLY AND OPPOSITELYMODULATED
IN ATC in vivo AND CANCER CELL LINES
Genes commonly up-regulated in ATC and cell lines were
involved in DNA replication and DNA metabolic processes. The
correlation, based on mRNA expression profiles, between cell
lines and ATC thus seems to be due to the strong proliferation
capacity of these two types of cells. Indeed, ATC is one of the
most proliferating human tumors and human thyroid cancer cell
lines have a strong proliferation capacity. In our data this property
was linked to ribosomal biosynthesis and translation pathways
for four cell lines. As expected, the genes found regulated in an
opposite direction between ATC and cell lines might reflect the
differences between in vivo tumors and in vitro cultures. They
are involved in the MHC class II pathway or in cell adhesion.
As mentioned above in the pathway analysis of the cell lines,
they abrogate gene expressions which are not necessary for their
survival and growth in in vitro cultures. The increase of those
genes in ATC, and the implication of this increase to growth and
survival of the tumor in vivo, would be interesting to explore.
However, there are a number of factors which could also explain
this increase. For instance, the potential presence of immune cells,
which express MHC class II in the tumor or the activation of the
MHC class II pathway in these cells by an inflammatory process,
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might explain an increase in these genes in ATC. In line with this,
thyrocytes indeed can express MHC class II after an inflamma-
tory stimulation and inflammation is often associated with tumor
development. Furthermore, the increase of expression might also
be due to a combination of the factors.
CONCLUSIONS
In this work, the aim was to further investigate the characteristics
of human thyroid cancer cell lines derived from different origins.
First, genetic alterations in six cell lines were in line with liter-
ature data and furthermore, the BRAF mutation in WRO cells
questions this cell line as a model for FTC, indeed this muta-
tion does not occur in FTC. Second, in five cell lines the MHC
class II pathway was down-regulated and in four of them, ribo-
some biosynthesis and translation pathways were up-regulated.
Third, by using microarray data from ATC, PTC, and FTC, we
have preliminary found that mRNA expression profiles of human
thyroid cancer cell lines, originally derived from ATC, poorly dif-
ferentiated PTC, FTC, or PTC, were closer to ATC. Specifically,
we found genes commonly up-regulated in ATC involved in DNA
replication which were also up-regulated in the thyroid cancer cell
lines, in accordance with their higher proliferation rate in vitro.
In summary, these results would suggest that some human PTC
or FTC derived cell lines (i.e., TPC-1) might have partially lost
their original DNA synthesis/replication regulation mechanisms
during their in vitro cell adaptation/evolution. Also, further com-
parisons using microarray data set from poorly differentiated
thyroid cancers are needed and could be a near future goal in our
laboratory.
During our study, the origin of the WRO cell line as thyroid
cancer cell line has been questioned. However, the pathway anal-
ysis and the comparisons of expression profiles showed similar
results for WRO cell line and the other thyroid cancer cell lines.
To address the origin of the WRO cell line, more complete anal-
yses (including cell lines from different cancer types) could be a
near future goal in our laboratory.
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